Dyslipidemia

Reaffirming their 2016 recommendation, the USPSTF concluded current evidence was insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents in their latest recommendation statement.

An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.

An analysis of data from the CLEAR Outcomes trial presented at ENDO 2023 suggests use of the non-statin lipid-lowering agent provided cardiovascular risk reduction comparable to statin therapy for each 1.0 mmol/L reduction in LDL-C.

New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe.

Each month, our editorial staff compiles a recap of the top news in cardiology from the past month. Our April 2023 month in review features new data and documents related to heart failure management, recaps and forecasts of top regulatory decisions, and other top news!

Data from the ARCHITECT trial detail the effects of alirocumab use on coronary plaque burden and characteristics in a cohort of patients with familial hypercholesterolemia but without atherosclerotic cardiovascular disease.

Data from a recent study suggests statin-associated muscle symptoms were not exacerbated as a result of moderate-intensity physical activity.

New research from the Family Heart Foundation indicates high-risk patients who fail to achieve LDL-C targets had a 49% greater rate of cardiovascular events than their counterparts who met LDL-C targets.

The US FDA has approved an indication for evinacumab for use as an adjunct to other lipid-lowering therapies in children with homozygous familial hypercholesterolemia as young as 5 years old, which makes evinacumab the first ANGPTL3 inhibitor indicted for this patient population.

With ACC 2023 in the rearview, the HCPLive editorial team compiled perspectives on the meeting’s top piece of news from half a dozen clinicians specializing in various subspecialties across the spectrum of cardiovascular care.

An analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials provides insight into the atherosclerotic cardiovascular risk associated with high-sensitivity C-reactive protein.

Deepak Bhatt, MD, MPH, discusses results of the phase 2 ENTRIGUE trial and how it informs clinicians on the effects of the human FGF21 analogue in patients with severe hypertriglyceridemia.

New research from a phase 2b trial presented at ACC 2023 suggests an oral PCSK9 inhibitor could help reduce LDL-C by 60% in patients with or at-risk for atherosclerotic cardiovascular disease.

Results of the CLEAR Outcomes trial suggests adherence to bempedoic acid was associated with a 13% relative reduction in incidence of the trial's primary endpoint of 4-point MACE, but no benefit was observed for risk of cardiovascular death or all-cause mortality in the trial.

An analysis of NHANES data from 1999-2018 details the progress made with regard to cholesterol management on a population level but also provides insight into areas where room for improvement still exists.

An analysis of data from the MESA study sheds further light on associations of lipoprotein(a) and cardiovascular risk among a primary prevention cohort.

Data from an analysis of patients in Denmark provides an overview of the effects of statin therapy on risk of intracerebral hemorrhage, with insights into how this benefit may vary based on the location of the intracerebral hemorrhage.

Almost 3 years after approval, Esperion's announcement of positive results from the CLEAR Outcomes trial indicate bempedoic acid is the first oral non-statin therapy to meet the MACE-4 primary endpoint included in the outcomes trial of the ATP citrate lyase inhibitor.

A cluster randomized trial from Penn Medicine's Nudge Unit provides insight into the effects of "nudges" in primary care settings for improving the prescription of statins.

Results of the RIDTS study suggest extending anticoagulation with rivaroxaban to 12 weeks as opposed to the traditional 6-week course could reduce recurrent venous thromboembolism in patients with symptomatic isolated DVT.

An analysis of statin initiators within the VITAL trial provides insight into the impact of vitamin D supplementation on the incidence of statin-associated muscle symptoms and statin discontinuation among participants in the trial.

New research comparing use of lipid biomarkers for predicitng coronary heart disease suggests HDL-C may not provide the cardioprotective benefits purported in previous data.

An analysis of data from Medicare beneficiaries receiving treatment over a decade-long period provides a snapshot of oral anticoagulation initiation and nonadherence among older patients with atrial fibrillation in the US.

Using data from 88 medical centers across the US, new data is providing clinicians with an overview of contemporary trends in DOAC and warfarin use in adult patients with nonvalvular atrial fibrillation at high risk for stroke over the past decade.

A 10,000-person study provides insight into the feasibility and effectiveness of participation an entirely remote hypertension and lipid management program in a diverse health care network.

Erin Michos, MD, provides further insight in an on-site interview AHA 22 related to results of the SPORT trial, which provide direct comparative insights into the impact of several dietary supplements and placebo therapy relative to low-dose statin therapy in a primary prevention cohort.

Results of the Ocean(a)-DOSE trial, a phase 2 dose-finding study presented at AHA 22, suggests use of olpasiran dosed at 75 mg or higher every 12 weeks was associated with a reduction of Lp(a) among 95% of patients.

Data from a phase 3 trial presented at AHA 22 suggests use of edoxaban could be a safe and effective method for reducing risk of thromboembolism in pediatric patients with cardiovascular disease considered to be at increased risk of thrombosis.

An analysis of the GWTG-Atrial Fibrillation Registry data suggests Black patients with AFib were 25% less likely to receive a prescription for oral anticoagulation at discharge and 27% less likely to receive a DOAC than their non-Hispanic White counterparts.

An analysis of data from a quality improvement initiative demonstrates the majority of patients continue their anticoagulant regimen beyond the guideline-directed 3 months following provoked VTE.